Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study

We evaluated the clinical efficacy and safety of the coadministration of a PDE5 inhibitor and an α-adrenergic blocker in patients with both benign prostatic hyperplasia/lower urinary tract symptoms (BPH-LUTS) and ED using mirodenafil 50 mg (Mvixx) once daily (OD) in patients already receiving stable...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of impotence research 2013-07, Vol.25 (4), p.149-154
Hauptverfasser:	Bang, W J, Oh, C Y, Yoo, C, Cho, J S, Yang, D Y, Lee, D H, Lee, S H, Chung, B H
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/2768/1753 692/700/565/1436 Adrenergic alpha-Antagonists - administration & dosage Adrenergic alpha-Antagonists - adverse effects Adult Aged Analysis Anti-impotence agents Blood pressure Blood Pressure - drug effects Dosage and administration Erectile dysfunction Erectile Dysfunction - complications Erectile Dysfunction - drug therapy Heart Rate - drug effects Humans Hypertrophy Lower Urinary Tract Symptoms - drug therapy Lower Urinary Tract Symptoms - etiology Male Medicine Medicine & Public Health Middle Aged original-article Phosphodiesterase 5 Inhibitors Phosphodiesterases Prospective Studies Prostate Prostatic Hyperplasia - complications Prostatic Hyperplasia - drug therapy Pyrimidinones - administration & dosage Pyrimidinones - adverse effects Reproductive Medicine rology Sulfonamides - administration & dosage Sulfonamides - adverse effects Urinary tract infections Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!